Compare HKD & BBNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HKD | BBNX |
|---|---|---|
| Founded | 2003 | 2015 |
| Country | France | United States |
| Employees | N/A | 423 |
| Industry | Finance: Consumer Services | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 499.7M | 493.1M |
| IPO Year | 2021 | N/A |
| Metric | HKD | BBNX |
|---|---|---|
| Price | $1.52 | $10.71 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $26.22 |
| AVG Volume (30 Days) | 590.1K | ★ 955.0K |
| Earning Date | 02-27-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $34.99 |
| Revenue Next Year | N/A | $34.47 |
| P/E Ratio | $14.10 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.26 | $8.89 |
| 52 Week High | $5.47 | $32.71 |
| Indicator | HKD | BBNX |
|---|---|---|
| Relative Strength Index (RSI) | 43.40 | 32.01 |
| Support Level | $1.34 | $9.91 |
| Resistance Level | $1.69 | $15.53 |
| Average True Range (ATR) | 0.10 | 0.62 |
| MACD | -0.02 | 0.22 |
| Stochastic Oscillator | 35.94 | 29.08 |
AMTD Digital Inc along with its subsidiaries, is mainly involved in the provision of digital solutions services. Its reportable segments are digital solutions services segment; hotel operations, hospitality and VIP services segment; media and entertainment services segment; and Strategic investments. The company generates maximum revenue from Digital solutions services segment, which provides its institutional and corporate clients with exclusive, paid access to enhance their investor communication, investor relations and corporate communication to potentially maximize their valuation, as well as providing digital solution services. Geographically, the company generates revenue from China, Hong Kong, Europe, Americas and Southeast Asia.
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.